(Q44297394)

English

Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

0 references

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

author name string

A Takala

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

M Apajasalo

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

N Zethraeus

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

G Kobelt

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

European Journal of Heart Failure

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

101-108

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12559222%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

The heart failure epidemic: exactly how big is it?

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Survival of patients with a new diagnosis of heart failure: a population based study

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Hospitalization of patients with heart failure: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

The current cost of heart failure to the National Health Service in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Myocardial efficiency during levosimendan infusion in congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Inotropic therapy for heart failure: an evidence-based approach.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Levosimendan: a new era for inodilator therapy for heart failure?

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Cost effectiveness of carvedilol for heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Economic impact of beta blockade in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Cost-effectiveness in clinical cardiology. Part 1: Coronary artery disease and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Accounting for future costs in medical cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Heart failure: a medical hydra

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Is the prognosis of heart failure improving?

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Troponin C–Mediated Calcium Sensitization Induced by Levosimendan Does Not Impair Relaxation

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

21 January 2018

Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2802%2900246-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44297394&oldid=2109255435"